NEW YORK (GenomeWeb News) – MetaStat today said it has reached two exclusive licensing agreements for the use of alternatively spliced mRNA and protein isoform biomarkers.
The agreements are with the Massachusetts Institute of Technology and its David H. Koch Institute for Integrative Cancer Research at MIT and its department of biology, the Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The technology being licensed is for the diagnosis, prognosis, and treatment of metastasis in epithelial solid tumor cancers.
MetaStat said the technology supports its IP surrounding the use of the Mena protein isoforms and provides it with additional targets for its companion diagnostic and therapeutic programs.
Financial and other terms of the deals were not disclosed.
"Alternatively spliced genes that drive tumor progression and resistance offer a unique opportunity for precision medicine in oncology as MetaStat builds the first platform that directly links a targeted therapeutic to its companion diagnostic based on the detection and targeting of alternatively spliced oncogenes," MetaStat Chief Scientific Officer of Therapeutics Elizabeth Buck said in a statement.